Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. NVDA
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMD
9. ATH
10. KLC

Go back to Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

August 5, 2021 7:30 AM EDT

Today Announced Agreement with Roche to Evaluate SY-5609 in Combination with Immunotherapy in BRAF-Mutant Colorectal Cancer Patients

Additional Dose Escalation Data for SY-5609 to be Highlighted in Oral Presentation at ESMO Congress; On Track to Advance into Phase 1 Expansion in 2H 2021

On Track to Initiate SELECT-AML-1 Randomized Phase 2 Trial of Tamibarotene in AML and Dose Confirmation Study for SY-2101 in APL in 2H 2021

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals... More